ReviewMuir-Torre syndrome (MTS): An update and approach to diagnosis and management
Section snippets
Pathogenesis
The majority of cases of MTS (MTS I) demonstrate autosomal dominant inheritance with high penetrance and variable expression. It may also occur sporadically, most commonly documented in transplant recipients.7
In the majority of cases of MTS (MTS I), germline mutations have been detected in mismatch repair (MMR) genes: Mutator S Homologue (MSH)2 (OMIM #609309), Mutator L Homologue (MLH)1 (OMIM #120436), MSH6 (OMIM #600678), and Postmeiotic Segregation Increased (PMS)2 (OMIM #600259). The MMR
Epidemiology
Overall, MTS has a male predilection, with a male to female ratio of 3:2.16 One study of 205 cases of MTS documented sebaceous tumors appearing before internal malignancy in 22% of cases, concurrently in 6% of cases, and after in 56% of cases; 16% of cases demonstrated no temporal relationship.17 The average age that sebaceous neoplasms present is 53 years, ranging from 21 to 88 years.17 In addition, cutaneous tumors occur as long as 25 years before or 37 years after visceral malignancy.18
Cutaneous tumors
Although sebaceous gland hyperplasia is frequently encountered in the general population, sebaceous neoplasms–adenoma, epithelioma, and carcinoma–are rarely seen, except in patients with MTS. Sebaceous adenoma is the most common subtype, with a frequency of 68%.19 Approximately one quarter (27%) of sebaceous neoplasms are sebaceous epitheliomas, and 30% are sebaceous carcinomas.18 Other cutaneous tumors include keratoacanthoma, basal cell carcinoma with sebaceous differentiation, and cystic
Histology
Sebaceous tumors often demonstrate “mulberry cells”, with vacuolated cytoplasm and starry nuclei (Table II and Fig 2). Lipid granules in the cytoplasm of the cells result in a characteristic “frothy” appearance. Sebaceous carcinomas tend to have overexpression of p53 and ki67 compared with other sebaceous neoplasms.37, 38, 39, 40 Keratoacanthomas may be histologically typical or may show sebaceous elements, designated as sebokeratoacanthomas41 (Fig 3). These tumors have a central crater with
Importance of solitary sebaceous adenoma
If an individual has a solitary sebaceous adenoma, the sebaceous neoplasm most closely linked with MTS, immunohistochemistry (IHC) testing should be performed on the tumor. Loss of staining of combinations of certain gene products appears to give 100% positive predictive value that the patient has MTS I. These include MLH1 and MSH2; and MLH1, MSH2, and MSH642 (Table III). In addition, the tumor should be subject to MSI gene analysis.
Diagnosis
Diagnosis of MTS is largely determined with existing diagnostic criteria that consist of at least 1 sebaceous neoplasm and at least 1 internal organ cancer at some point in the patient's life without other contributory factors, such as radiotherapy or AIDS.3 In addition, a family history of MTS with a personal history of multiple keratoacanthomas or keratoacanthomas in areas not exposed to sunlight also suggest the diagnosis (Table IV).
Dermoscopy and reflectance confocal microscopy have been
Differential diagnosis
Several other genetic disorders may be considered in patients with cutaneous nodules. These disorders include Gardner syndrome (OMIM #175100), Cowden syndrome (OMIM #158350), Brooke-Spiegler syndrome (OMIM #605041), basal cell nevus syndrome (OMIM #109400), Ferguson-Smith syndrome (OMIM #132800), and tuberous sclerosis (OMIM #191100).
Treatment
Most cutaneous cancers in MTS are treated with complete excision. Sebaceous carcinomas have the potential for angioinvasion and metastases, and therefore require wide local excision with 5- to 6-mm margins; frozen section control may be used to confirm sufficient margins.54 Recurrence rates range from 4% to 28%.37 Mohs micrographic surgery is also appropriate for sebaceous carcinoma. Radiation therapy is often used as an adjuvant to excision after recurrence. However, if used as a sole
Approach to diagnosis and management
We provide an approach to diagnosing MTS and treating patients, using modified diagnostic criteria based on the Schwartz and Torre3 criteria (Fig 4). The appearance of a sebaceous gland neoplasm or multiple keratoacanthomas should prompt a thorough discussion about family (first- and second-degree relatives) and personal history of internal malignancies. Before subjecting lesions to further testing, patient consent should be obtained.70 In addition, as per the United Nations International
References (72)
- et al.
The Muir-Torre syndrome: a 25-year retrospect
J Am Acad Dermatol
(1995) - et al.
Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer
Gastroenterology
(2010) - et al.
The cutaneous effects of post-transplant immunosuppression with cyclosporine in Muir-Torre syndrome
J Am Acad Dermatol
(2011) - et al.
Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome
Am J Transplant
(2007) - et al.
Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature
J Am Acad Dermatol
(1999) - et al.
Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome
Am J Med
(1991) - et al.
Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer
Gastroenterology
(1997) - et al.
MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome
Mod Pathol
(2008) - et al.
Sebaceous neoplasms and the immunoprofile of mismatch-repair proteins as a screening target for syndromic cases
Pathol Res Pract
(2015) - et al.
BRAF/KRAS gene sequencing of sebaceous neoplasms after mismatch repair protein analysis
Hum Pathol
(2014)
A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome
Genet Med
Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy
J Am Acad Dermatol
Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer
Gastroenterology
Discrimination between defects in elongation fidelity and termination efficiency provides mechanistic insights into translational readthrough
J Mol Biol
Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face
Br J Surg
Multiple sebaceous tumors
Arch Dermatol
The frequency of Muir-Torre syndrome among Lynch syndrome families
J Natl Cancer Inst
The Muir-Torre syndrome: a disease of sebaceous and colonic neoplasms
Dermatologica
Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms
J Genet Couns
Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients
Fam Cancer
A novel complex mutation in MSH2 contributes to both Muir-Torre and Lynch syndrome
J Hum Genet
Attenuated familial adenomatous polyposis and Muir-Torre syndrome linked to compound biallelic constitutional MYH gene mutations
Clin Genet
Prevalence of MYH germline mutations in Swiss APC mutation-negative polyposis patients
Int J
Muir-Torre syndrome–an uncommon localization of sebaceous carcinomas following irradiation
Acta Oncol (Stockholm, Sweden)
Sebaceous carcinoma of the suprapubic area in a liver transplant recipient
Ann Dermatol
Muir-Torre syndrome
Dermatol Online J
Keratoacanthoma: a clinico-pathologic enigma
Dermatol Surg
Muir-Torre syndrome: diagnostic and screening guidelines
Australas J Dermatol
Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia
Am J Surg Pathol
A case of sebaceous carcinoma diagnosed in an adolescent male
J Cutan Pathol
Cystic sebaceous tumors as marker lesions for the Muir-Torre syndrome: a histopathologic and molecular genetic study
Am J Dermatopathol
Considerations on the performance of immunohistochemistry for mismatch repair gene proteins in cases of sebaceous neoplasms and keratoacanthomas with reference to Muir-Torre syndrome
Am J Dermatopathol
Family with MSH2 mutation presenting with keratoacanthoma and precancerous skin lesions
J Dermatol
The Torre syndrome with gastrointestinal polyposis
Arch Dermatol
Expanded extracolonic tumor spectrum in MUTYH-associated polyposis
Gastroenterology
The liver: another organ involved in Muir Torre syndrome?
Fam Cancer
Cited by (0)
Funding sources: None.
Conflicts of interest: None declared.